Page 143 | Certara

Blog

Trends for Market Access, HEOR, and Real World Evidence

This blog reviews trends for using health economics and outcomes research and real-world evidence to…

CertaraMay 10, 2019

Announcement

Introducing P21 Community 3.0

May 7, 2019 We are thrilled to announce that P21 Community 3.0 is available for immediate…

CertaraMay 7, 2019

Poster

Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors

CertaraMay 2, 2019

Poster

Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models

CertaraApril 22, 2019

Poster

Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics

CertaraApril 22, 2019

Poster

Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients

CertaraApril 22, 2019

Poster

Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies

CertaraApril 22, 2019

Poster

Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation

CertaraApril 22, 2019

Announcement

New Pinnacle 21 Enterprise 4.0 Eases Concern about PMDA Submissions

April 2, 2019 Released March 31, the new P21 Enterprise 4.0 provides more options for…

CertaraApril 2, 2019

Blog

Real World Evidence Marches Forward in Drug Development

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…

CertaraMarch 20, 2019

© 2025 Certara. All Rights Reserved. | Legal | Privacy policy